---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-23-000064"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:41:47.747676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint

## Summary
- Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.
- Cash $453.3M at Sep 30, down $130.9M; reaffirms cash runway through year-end 2026.
- Imsidolimab Phase 3 GPP: 53.3% achieved GPPPGA 0/1 vs 13.3% placebo (p=0.0131); out-license planned in 2024.
- Initiated Phase 2b rosnilimab RA trial (420 pts); Phase 2 UC trial starting Q4 2023; top-line mid-2025 and H1 2026.
- Collaboration revenue from Jemperli royalties $3.3M (vs $1.3M) helped offset net loss expansion.

## SEC filing metadata
- accession: 0001370053-23-000064
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000064/0001370053-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000064/anab-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-23-000064
- JSON: https://secwatch.observer/filing/0001370053-23-000064.json
- Plain text: https://secwatch.observer/filing/0001370053-23-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.